Abstract:Objective:To evaluate the efficacy and security of preoperative brachyther-apy combinded concurrent chemotherapy ( preoperative brachy-chemothepapy ) in the compre-hensive treatment for patients with FIGO stage ⅠB2 andⅡA2 cervical cancer. Methods:Total of 82 patients with FIGO stage ⅠB2 andⅡA2 cervical cancer were enrolled retrospectively treated in the department of Gynaecology of Drum Tower Hospital affiliated to Medical College of Nanjing University from June 2010 to May 2015 . According to the different preoperative regi-mens,they were categorized into three groups,including directly surgical group ( Group A,27 cases) ,neoadjuvant chemotherapy group ( Group B,41 cases) ,and brachy-chemotherapy group ( Group C,14 cases) . Radical hysterectomy was performed following the later two regimens. To compare three groups of postoperative hospital stay, average intraoperative blood loss, average surgical time,clinical pathological remission rate,incidence of complications and recent survive time. Results:Postoperative hospital stay was significantly more in group B than group A. Intra-operative blood loss was significantly more in group B than in group C. These difference were statistically significant (P<0. 05). Vascular invasion rate,deep muscle invasion rate and lymph node positive rate in group C were lower than in group A and B. All these difference were statis-tically significant (P<0. 05),and no statistically significant difference were noted in latter two groups (P>0. 05),and three groups had no significant difference in nerve invasion rate (P>0. 05 ) . The preoperative therapeutic effective rate of 85 . 7% in group C was much higher than 36 . 4% in group B with a statistically significant difference ( P<0 . 05 ) . The occurrence rate of sur-gery-related complications and nerve invasion rate had no statistically significant difference a-mong three groups. Median survival time and 3-year survival rate in group A,B and C were 41. 2 months(95%CI:33. 8 ~48. 5 months) and 63. 9%,33. 8 months(95%CI:28. 9 ~38. 7 months)and 53. 1%,48. 1 months(95%CI:37. 5 ~58. 7 months)and 68. 2% respectively, where there were no statistically significant difference among three groups ( P>0 . 05 ) . Lymph node metastasis was a independent risk factor of decreasing survival time ( P<0 . 05 ) . Conclu-sions:For no-significantly increasing the occurrence rate of surgery-related complications,surgi-cal time,intraoperative blood loss,preoperative brachytherapy combinded concurrent chemother-apy is a safe and effective regimen for patients with stage ⅠB2 andⅡA2 cervical cancer.

The Nursing Cooperation in Brachytherapy on the Patients with Clinically Localized Intermediate and High-risk Prostate Cancer

Analysis of efficacy and adverse events of brachytherapy for prostate cancer

Local Advanced Prostate Cancer Treated by Combination of ~(125)I Brachytherapy and Surgical Castrati(Report of 40 Cases)

[Research of efficacy of brachytherapy for localized prostate cancer].

Short-term efficacy and security of preoperative afterloading brachytherapy combinded concurrent chemotherapy for patients with FIGO stage ⅠB2 and Ⅱ A2 cervical cancer

125I Brachytherapy of Locally Advanced Non-Small-cell Lung Cancer after One Cycle of First-Line Chemotherapy: a Comparison with Best Supportive Care.

Progress of Clinical Brachytherapy Application

Survival analysis of radical prostatectomy and brachytherapy in the treatment of early-stage localized prostate cancer

Clinical application and accuracy assessment of imaging-based surgical navigation guided <SUP>125</SUP>I interstitial brachytherapy in deep head and neck regions

Radiation Physics, Quality Control, and Quality Assurance of Lung Cancer Brachytherapy with 125I Particles

Effect of nurse-physician collaboration on the incidence of complications, negative emotions and quality of life in cervical cancer patients: a randomized controlled study

Efficacy and Safety of Brachytherapy for Localized Prostate Cancer in Renal Transplant Recipients

Computed Tomography–Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non–Small Cell Lung Cancer: A Phase 1 Clinical Trial

Understanding stereotactic radiosurgery for intracranial tumors, seed implants for prostate cancer, and intravascular brachytherapy for cardiac restenosis

CT-guided Interstitial Brachytherapy of Inoperable Non-Small Cell Lung Cancer.

Primary Result of Early Parotid Gland Carcinomas with Optimized Target Design Brachytherapy

Long-term efficacy of hyperfractionated intracavitary brachytherapy on 69 patients with locally recurrent nasopharyngeal carcinoma

The New Advances of Brachytherapy for Localized Prostate Cancer

Efficacy of Brachytherapy Concomitant with Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil in Unresectable Head and Neck Squamous Cell Carcinoma.

Clinical analysis of permanent 125I prostate brachytherapy monotherapy for early prostate cancer ( report of 18 cases)

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort